SHELTON, CT / ACCESS Newswire / May 26, 2026 / NanoViricides, Inc. (NYSE American:NNVC) (the "Company"), a clinical stage leader developing antiviral drugs that viruses cannot escape, compares potenti ...

NexusHealth has an extensive ecosystem of experts – including innovation and commercialization leaders at McMaster – in all ...

The fast-growing Ebola outbreak in the Democratic Republic of Congo came to the world’s attention only a little more than a ...

The experimental drug daraxonrasib, which doubled survival time in patients with advanced pancreatic cancer, may also prove effective for lung, colon and ovarian cancers.

The Vaccines and Related Biological Products Advisory Committee (VRBPAC) also discussed the need to target the long-simmering ...

Revolution Medicines Inc.’s experimental pancreatic cancer drug daraxonrasib delayed painful symptoms for months, in addition ...

The highly anticipated results of a clinical trial for the pill, daraxonrasib, have been released, giving doctors hope for ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

A first-of-its-kind drug for hepatitis B is letting some patients stop treatment without showing signs of the dangerous liver virus, what’s called a “functional cure,” researchers reported Thursday.

The targeted therapy sunvozertinib was more effective than standard platinum-based chemotherapy as a first-line treatment for patients with advanced non-small cell lung cancer (NSCLC) driven by EGFR ...

CEO Mark Goldsmith says Revolution Medicines will submit pancreatic cancer drug daraxonrasib for FDA approval soon.

Overlapping deadly outbreaks of hantavirus and Ebola have fuelled a resurgence of misinformation on social media, including posts repeating an unproven medical assertion the diseases can be treated by ...